{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:37:43Z","timestamp":1776087463127,"version":"3.50.1"},"reference-count":31,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Prader-Willi syndrome (PWS) is a rare neurodevelopmental genetic disorder. In adults, the syndrome is characterised by muscular hypotonia, a different body composition with more body fat than muscle mass, hyperphagia, behavioural problems, and cognitive dysfunction. Endocrine deficiencies are common, including growth hormone (GH) deficiency. Here, we present data from a cross-sectional study in adults with PWS with a focus on the long-term safety of GH treatment. A total of 22 patients (14 men) were treated with GH for a median of 20 years. Data on body composition, hormones, and metabolic parameters were retrieved from the patients\u2019 medical records. The median age was 27 years. The median GH dose was 0.5 mg\/day. Insulin-like growth factor 1 (IGF-I) and blood lipids were normal, while fasting glucose and HbA1c were slightly elevated in three men with diabetes. Fat mass was less than fat free mass in all, though this was less pronounced in women. GH treatment did not negatively affect the metabolic profile, and none developed cardiovascular diseases or cancer. All adults on long-term GH treatment had a normal body composition and our results indicate that treatment was safe. However, PWS is a complex, multisystemic disease and continuous, individual considerations are required during GH treatment, especially in patients with risk factors for adverse effects.<\/jats:p>","DOI":"10.3390\/jcm10122667","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T11:20:26Z","timestamp":1623928826000},"page":"2667","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Twenty Years of GH Treatment in Adults with Prader-Willi Syndrome"],"prefix":"10.3390","volume":"10","author":[{"given":"Anna","family":"Sj\u00f6str\u00f6m","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry, Karolinska University Hospital, 171 76 Stockholm, Sweden"},{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3980-1927","authenticated-orcid":false,"given":"Charlotte","family":"H\u00f6ybye","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden"},{"name":"Department of Endocrinology, Karolinska University Hospital, 171 76 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/gim.0b013e31822bead0","article-title":"Prader-Willi syndrome","volume":"14","author":"Cassidy","year":"2012","journal-title":"Genet. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s40618-015-0312-9","article-title":"Prader-Willi syndrome: A review of clinical, genetic, and endocrine findings","volume":"38","author":"Angulo","year":"2015","journal-title":"J. Endocrinol. Investig."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"A504","DOI":"10.1210\/jendso\/bvaa046.993","article-title":"SUN-604 U.S. Prevalence & Mortality of Prader-Willi Syndrome: A Population-Based Study of Medical Claims","volume":"4","author":"McCandless","year":"2020","journal-title":"J. Endocr. Soc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1210\/edrv.22.6.0447","article-title":"Endocrine dysfunction in Prader-Willi syndrome: A review with special reference to GH","volume":"22","author":"Burman","year":"2001","journal-title":"Endocr. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Tauber, M., and Hoybye, C. (2021). Endocrine disorders in Prader-Willi syndrome: A model to understand and treat hypothalamic dysfunction. Lancet Diabetes Endocrinol.","DOI":"10.1016\/S2213-8587(21)00002-4"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/ajmg.a.33951","article-title":"Nutritional phases in Prader-Willi syndrome","volume":"155","author":"Miller","year":"2011","journal-title":"Am. J. Med Genet. Part A"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/NDT.S5560","article-title":"Clinical management of behavioral characteristics of Prader\u2013Willi syndrome","volume":"6","author":"Dimitropoulos","year":"2010","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00776-014-0641-0","article-title":"Growth hormone treatment for osteoporosis in patients with scoliosis of Prader-Willi syndrome","volume":"19","author":"Nakamura","year":"2014","journal-title":"J. Orthop. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"E1072","DOI":"10.1210\/jc.2012-3888","article-title":"Growth Hormone Research Society Workshop Summary: Consensus Guidelines for Recombinant Human Growth Hormone Therapy in Prader-Willi Syndrome","volume":"98","author":"Deal","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/cen.14372","article-title":"The use of growth hormone therapy in adults with Prader-Willi syndrome: A systematic review","volume":"94","author":"Frixou","year":"2021","journal-title":"Clin. Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1651-2227.2006.00051.x","article-title":"Five-years growth hormone (GH) treatment in adults with Prader-Willi syndrome","volume":"96","year":"2007","journal-title":"Acta Paediatr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/apa.12898","article-title":"Growth hormone treatment of Prader-Willi syndrome has long-term, positive effects on body composition","volume":"104","year":"2015","journal-title":"Acta Paediatr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"274","DOI":"10.21037\/tp.2017.09.04","article-title":"Review of Prader-Willi syndrome: The endocrine approach","volume":"6","author":"Heksch","year":"2017","journal-title":"Transl. Pediatr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00075197-200111000-00006","article-title":"Gender differences in fat metabolism","volume":"4","author":"Blaak","year":"2001","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1210\/jc.2013-3607","article-title":"Skeletal Muscle Characteristics and Motor Performance after 2-Year Growth Hormone Treatment in Adults with Prader-Willi Syndrome","volume":"99","author":"Lafortuna","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/BF03349255","article-title":"Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome","volume":"31","author":"Gondoni","year":"2008","journal-title":"J. Endocrinol. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ghir.2011.05.002","article-title":"Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome","volume":"21","author":"Farholt","year":"2011","journal-title":"Growth Horm. IGF Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/14740338.2020.1839410","article-title":"Safety of current recombinant human growth hormone treatments for adults with growth hormone deficiency and unmet needs","volume":"19","author":"Simsek","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11102-020-01079-3","article-title":"Effect of long-term growth hormone replacement on glucose metabolism in adults with growth hormone deficiency: A systematic review and meta-analysis","volume":"24","author":"Zhou","year":"2021","journal-title":"Pituitary"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2265.2011.04303.x","article-title":"Effects of recombinant human growth hormone therapy in adults with Prader-Willi syndrome: A meta-analysis","volume":"77","author":"Klibanski","year":"2012","journal-title":"Clin. Endocrinol."},{"key":"ref_21","first-page":"1","article-title":"Update on Diabetes Mellitus and Glucose Metabolism Alterations in Prader-Willi Syndrome","volume":"20","author":"Grugni","year":"2020","journal-title":"Curr. Diabetes Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1210\/jcem.86.9.7814","article-title":"Visceral Adipose Tissue and Metabolic Complications of Obesity Are Reduced in Prader-Willi Syndrome Female Adults: Evidence for Novel Influences on Body Fat Distribution","volume":"86","author":"Goldstone","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1210\/jcem.87.8.8735","article-title":"Metabolic Profile and Body Composition in Adults with Prader-Willi Syndrome and Severe Obesity","volume":"87","author":"Hilding","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.numecd.2016.05.010","article-title":"Disorders of glucose metabolism in Prader\u2013Willi syndrome: Results of a multicenter Italian cohort study","volume":"26","author":"Fintini","year":"2016","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2147\/DMSO.S141352","article-title":"Obesity management in Prader\u2013Willi syndrome: Current perspectives","volume":"11","author":"Fintini","year":"2018","journal-title":"Diabetes Metab. Syndr. Obes. Targets Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2147\/TCRM.S70068","article-title":"Growth hormone therapy for Prader\u2013Willi syndrome: Challenges and solutions","volume":"12","author":"Grugni","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/ijo.2017.139","article-title":"Long-term health outcomes in patients with Prader\u2013Willi Syndrome: A nationwide cohort study in Denmark","volume":"41","author":"Hedgeman","year":"2017","journal-title":"Int. J. Obes."},{"key":"ref_28","first-page":"248","article-title":"Prevalence of, and risk factors for, physical ill-health in people with Prader-Willi syndrome: A population-based study","volume":"44","author":"Butler","year":"2002","journal-title":"Dev. Med. Child. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ghir.2015.12.002","article-title":"Variability in adherence to rhGH treatment: Socioeconomic causes and effect on children\u2019s growth","volume":"26","author":"Murillo","year":"2016","journal-title":"Growth Horm. IGF Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ghir.2015.07.004","article-title":"Status of long-acting-growth hormone preparations\u20142015","volume":"25","author":"Cohen","year":"2015","journal-title":"Growth Horm. IGF Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e2121","DOI":"10.1210\/clinem\/dgz149","article-title":"Long-Acting Growth Hormone Preparations\u2013Current Status and Future Considerations","volume":"105","author":"Miller","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/12\/2667\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:17:28Z","timestamp":1760163448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/12\/2667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["jcm10122667"],"URL":"https:\/\/doi.org\/10.3390\/jcm10122667","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]}}}